Cargando…

Identification of B-Cell Epitopes for Eliciting Neutralizing Antibodies against the SARS-CoV-2 Spike Protein through Bioinformatics and Monoclonal Antibody Targeting

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a global public health crisis. Effective COVID-19 vaccines developed by Pfizer-BioNTech, Moderna, and Astra Zeneca have made significant impacts in controlling the COVID-19 burden, especially in reducing the transmission of SARS...

Descripción completa

Detalles Bibliográficos
Autores principales: Lim, Hui Xuan, Masomian, Malihe, Khalid, Kanwal, Kumar, Asqwin Uthaya, MacAry, Paul A., Poh, Chit Laa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9029629/
https://www.ncbi.nlm.nih.gov/pubmed/35457159
http://dx.doi.org/10.3390/ijms23084341
_version_ 1784691926735257600
author Lim, Hui Xuan
Masomian, Malihe
Khalid, Kanwal
Kumar, Asqwin Uthaya
MacAry, Paul A.
Poh, Chit Laa
author_facet Lim, Hui Xuan
Masomian, Malihe
Khalid, Kanwal
Kumar, Asqwin Uthaya
MacAry, Paul A.
Poh, Chit Laa
author_sort Lim, Hui Xuan
collection PubMed
description Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a global public health crisis. Effective COVID-19 vaccines developed by Pfizer-BioNTech, Moderna, and Astra Zeneca have made significant impacts in controlling the COVID-19 burden, especially in reducing the transmission of SARS-CoV-2 and hospitalization incidences. In view of the emergence of new SARS-CoV-2 variants, vaccines developed against the Wuhan strain were less effective against the variants. Neutralizing antibodies produced by B cells are a critical component of adaptive immunity, particularly in neutralizing viruses by blocking virus attachment and entry into cells. Therefore, the identification of protective linear B-cell epitopes can guide epitope-based peptide designs. This study reviews the identification of SARS-CoV-2 B-cell epitopes within the spike, membrane and nucleocapsid proteins that can be incorporated as potent B-cell epitopes into peptide vaccine constructs. The bioinformatic approach offers a new in silico strategy for the mapping and identification of potential B-cell epitopes and, upon in vivo validation, would be useful for the rapid development of effective multi-epitope-based vaccines. Potent B-cell epitopes were identified from the analysis of three-dimensional structures of monoclonal antibodies in a complex with SARS-CoV-2 from literature mining. This review provides significant insights into the elicitation of potential neutralizing antibodies by potent B-cell epitopes, which could advance the development of multi-epitope peptide vaccines against SARS-CoV-2.
format Online
Article
Text
id pubmed-9029629
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-90296292022-04-23 Identification of B-Cell Epitopes for Eliciting Neutralizing Antibodies against the SARS-CoV-2 Spike Protein through Bioinformatics and Monoclonal Antibody Targeting Lim, Hui Xuan Masomian, Malihe Khalid, Kanwal Kumar, Asqwin Uthaya MacAry, Paul A. Poh, Chit Laa Int J Mol Sci Review Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a global public health crisis. Effective COVID-19 vaccines developed by Pfizer-BioNTech, Moderna, and Astra Zeneca have made significant impacts in controlling the COVID-19 burden, especially in reducing the transmission of SARS-CoV-2 and hospitalization incidences. In view of the emergence of new SARS-CoV-2 variants, vaccines developed against the Wuhan strain were less effective against the variants. Neutralizing antibodies produced by B cells are a critical component of adaptive immunity, particularly in neutralizing viruses by blocking virus attachment and entry into cells. Therefore, the identification of protective linear B-cell epitopes can guide epitope-based peptide designs. This study reviews the identification of SARS-CoV-2 B-cell epitopes within the spike, membrane and nucleocapsid proteins that can be incorporated as potent B-cell epitopes into peptide vaccine constructs. The bioinformatic approach offers a new in silico strategy for the mapping and identification of potential B-cell epitopes and, upon in vivo validation, would be useful for the rapid development of effective multi-epitope-based vaccines. Potent B-cell epitopes were identified from the analysis of three-dimensional structures of monoclonal antibodies in a complex with SARS-CoV-2 from literature mining. This review provides significant insights into the elicitation of potential neutralizing antibodies by potent B-cell epitopes, which could advance the development of multi-epitope peptide vaccines against SARS-CoV-2. MDPI 2022-04-14 /pmc/articles/PMC9029629/ /pubmed/35457159 http://dx.doi.org/10.3390/ijms23084341 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Lim, Hui Xuan
Masomian, Malihe
Khalid, Kanwal
Kumar, Asqwin Uthaya
MacAry, Paul A.
Poh, Chit Laa
Identification of B-Cell Epitopes for Eliciting Neutralizing Antibodies against the SARS-CoV-2 Spike Protein through Bioinformatics and Monoclonal Antibody Targeting
title Identification of B-Cell Epitopes for Eliciting Neutralizing Antibodies against the SARS-CoV-2 Spike Protein through Bioinformatics and Monoclonal Antibody Targeting
title_full Identification of B-Cell Epitopes for Eliciting Neutralizing Antibodies against the SARS-CoV-2 Spike Protein through Bioinformatics and Monoclonal Antibody Targeting
title_fullStr Identification of B-Cell Epitopes for Eliciting Neutralizing Antibodies against the SARS-CoV-2 Spike Protein through Bioinformatics and Monoclonal Antibody Targeting
title_full_unstemmed Identification of B-Cell Epitopes for Eliciting Neutralizing Antibodies against the SARS-CoV-2 Spike Protein through Bioinformatics and Monoclonal Antibody Targeting
title_short Identification of B-Cell Epitopes for Eliciting Neutralizing Antibodies against the SARS-CoV-2 Spike Protein through Bioinformatics and Monoclonal Antibody Targeting
title_sort identification of b-cell epitopes for eliciting neutralizing antibodies against the sars-cov-2 spike protein through bioinformatics and monoclonal antibody targeting
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9029629/
https://www.ncbi.nlm.nih.gov/pubmed/35457159
http://dx.doi.org/10.3390/ijms23084341
work_keys_str_mv AT limhuixuan identificationofbcellepitopesforelicitingneutralizingantibodiesagainstthesarscov2spikeproteinthroughbioinformaticsandmonoclonalantibodytargeting
AT masomianmalihe identificationofbcellepitopesforelicitingneutralizingantibodiesagainstthesarscov2spikeproteinthroughbioinformaticsandmonoclonalantibodytargeting
AT khalidkanwal identificationofbcellepitopesforelicitingneutralizingantibodiesagainstthesarscov2spikeproteinthroughbioinformaticsandmonoclonalantibodytargeting
AT kumarasqwinuthaya identificationofbcellepitopesforelicitingneutralizingantibodiesagainstthesarscov2spikeproteinthroughbioinformaticsandmonoclonalantibodytargeting
AT macarypaula identificationofbcellepitopesforelicitingneutralizingantibodiesagainstthesarscov2spikeproteinthroughbioinformaticsandmonoclonalantibodytargeting
AT pohchitlaa identificationofbcellepitopesforelicitingneutralizingantibodiesagainstthesarscov2spikeproteinthroughbioinformaticsandmonoclonalantibodytargeting